The Kimberly-Clark/Kenvue transaction is one of the worst-received major merger deals in recent years. Investors wondered why ...

The recent publicity could allow the company to get a good deal on Kenvue, which makes Tylenol, Band-Aids, and other ...

Kimberly-Clark is acquiring Tylenol maker Kenvue in a $48.7 billion cash-and-stock deal, creating a major consumer health goods company if shareholders approve.

A number of prominent hedge funds are likely applauding Monday’s news that Kimberly-Clark Corp. has agreed to acquire Kenvue ...

Potentially huge legal issues are hovering over Kenvue. But Kimberly-Clark, which agreed to buy it for $40 billion, appears ...

"Kimberly-Clark buys troubled Tylenol-maker Kenvue for $48.7bn" was originally created and published by Pharmaceutical ...

Despite a headline beat and decent revenue forecast, the poor reaction to the update from AI and data analytics darling ...

Consumer giant Kimberly-Clark has agreed to buy Kenvue, the parent company of embattled brand Tylenol, for nearly $49 billion. But what does this mean for consumers and shareholders?

Under the agreement, each Kenvue Inc. (NYSE:KVUE) shareholder would receive $3.5 per share in cash as well as 0.14625 ...

Asian shares were trading mixed on Tuesday after overseas markets got a big lift from optimism over AI technology. Japan’s benchmark Nikkei 225 dipped 0.5% to 52,163.84, coming ...

The consumer health and wellness giants are both Dividend Kings, with more than 50 years of consecutive annual payout ...